Breaking News Instant updates and real-time market news.

HFC

HollyFrontier

$48.48

(0.00%)

, JNJ

Johnson & Johnson

$136.53

(0.00%)

09:40
04/16/19
04/16
09:40
04/16/19
09:40

Unusually active option classes on open April 16th

Unusual total active option classes on open include: HollyFrontier (HFC), Johnson & Johnson (JNJ), UnitedHealth (UNH), Occidental Petroleum (OXY), McDermott (MDR), SPDR Gold Trust (GLD), Western Digital (WDC), IBM (IBM), Starbucks (SBUX), and Goldman Sachs (GS).

HFC

HollyFrontier

$48.48

(0.00%)

JNJ

Johnson & Johnson

$136.53

(0.00%)

UNH

UnitedHealth

$230.41

(0.00%)

OXY

Occidental Petroleum

$63.34

(0.00%)

MDR

McDermott

$9.15

(0.00%)

GLD

SPDR Gold Shares

$121.61

(0.00%)

WDC

Western Digital

$51.86

(0.00%)

IBM

IBM

$143.98

(0.00%)

SBUX

Starbucks

$76.15

(0.00%)

GS

Goldman Sachs

$199.77

(0.00%)

  • 16

    Apr

  • 16

    Apr

  • 16

    Apr

  • 25

    Apr

  • 25

    Apr

  • 29

    Apr

  • 29

    Apr

  • 30

    Apr

  • 02

    May

  • 02

    May

  • 02

    May

  • 07

    May

  • 08

    May

  • 10

    May

  • 29

    May

HFC HollyFrontier
$48.48

(0.00%)

02/08/19
TUDR
02/08/19
DOWNGRADE
TUDR
Hold
HollyFrontier downgraded to Hold from Buy at Tudor Pickering
04/16/19
GSCO
04/16/19
DOWNGRADE
GSCO
Sell
Goldman downgrades HollyFrontier to Sell, see 5% total return downside
Goldman Sachs analyst Neil Mehta downgraded HollyFrontier to Sell from Neutral and lowered his price target for the shares to $45 from $53. The analyst now sees a less attractive crude differential environment given a narrower Brent-WTI and WTI-WCS spread forecast in 2019 and 2020. Further, he has continued concerns around HollyFrontier's specialties business amid base oil oversupply and notes the company's recent operational execution has been below expectations. Mehta sees 5% total return downside.
04/16/19
GSCO
04/16/19
DOWNGRADE
Target $45
GSCO
Sell
HollyFrontier downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Neil Mehta downgraded HollyFrontier to Sell from Neutral and lowered his price target for the shares to $45 from $53.
02/12/19
MSCO
02/12/19
INITIATION
Target $65
MSCO
Equal Weight
HollyFrontier resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst Benny Wong resumed coverage of HollyFrontier with an Equal Weight rating and $65 price target, stating that while he expects it to benefit from the refining upcycle and IMO 2020 tailwinds he sees better valuation in other stocks in the sector.
JNJ Johnson & Johnson
$136.53

(0.00%)

04/09/19
PIPR
04/09/19
NO CHANGE
Target $32
PIPR
Neutral
Alkermes' ALPINE data an incremental positive, says Piper Jaffray
After Alkermes (ALKS) reported this morning that its ALPINE trial met its primary endpoint and that Aristada showed similar efficacy to the current market leader, Invega Sustenna, at all time points assessed, Piper Jaffray analyst Danielle Brill said she views the data as an incremental positive. However, she thinks it will be challenging to capture share from Johnson & Johnson (JNJ), telling investors that she is "not sure these data will be enough to move the needle." Brill maintains a Neutral rating on Alkermes.
04/09/19
NEED
04/09/19
UPGRADE
Target $3
NEED
Buy
Geron upgraded to Buy from Hold at Needham
Needham analyst Chad Messer upgraded Geron (GERN) to Buy with a price target of $3, saying the return of development rights for imetelstat in September by Janssen (JNJ) has created a "buying opportunity". The analyst cites the program's subsequent readouts from Phase II IMbark and IMerge studies in myelofibrosis and myelodysplastic syndrome, which he states has "established efficacy in both patient populations." Messer further contends that big pharma passing on imetelstat does not reflect a fundamental issue with the drug itself.
04/08/19
PIPR
04/08/19
NO CHANGE
Target $20
PIPR
Overweight
Immunomedics deal with J&J indicates sacituzumab re-filing, says Piper Jaffray
Immunomedics (IMMU) this morning announced that it has entered into an agreement with Johnson & Johnson (JNJ) to provide detailing services to J&J for erdafitinib in the U.S. through Q1 of 2020, Piper Jaffray analyst Joseph Catanzaro tells investors in a research note. The analyst believes the deal will provide incremental revenue to Immunomedics while allowing the company to keep its sacituzumab-trained sales team on board while offsetting some of the costs. Further, the Q1 of 2020 termination suggests a potential timeline for a sacituzumab re-filing and approval, says Catanzaro, who notes Immunomedics has not yet provided guidance. The analyst remains comfortable with his mid-2020 approval timing for sacituzumab and keeps an Overweight rating on Immunomedics with a $20 price target.
04/05/19
PIPR
04/05/19
NO CHANGE
Target $325
PIPR
Overweight
Piper a 'little cautious' on Q2 results for Cooper Companies
After speaking with a contact lens distributor, Piper Jaffray analyst Matt O'Brien is a "little cautious" on Cooper Companies' fiscal Q2 results. The shift to dailies continues, which is positive for the market as a whole, but Johnson & Johnson (JNJ) and Alcon were more aggressive in calendar Q1, so results for the category "may be a bit unusual," O'Brien tells investors in a research note. In addition to the "odd activity" from the two largest players, the analyst also heard about some "aggressive behavior" from Cooper in recent weeks, which makes him think the company should hit its numbers. He's still bullish on Cooper Companies capturing share in lenses in 2019 and 2020 and keeps an Overweight rating on the name.
UNH UnitedHealth
$230.41

(0.00%)

04/01/19
PIPR
04/01/19
NO CHANGE
PIPR
Overweight
Myriad traded lower on 'minor' United Healthcare change, says Piper Jaffray
Shares of Myriad Genetics closed Friday down 4% after United Healthcare (UNH) added a Current Procedural Terminology code and simplified the coverage rationale on its existing medical policy for pharmacogenetics, Piper Jaffray analyst William Quirk tells investors in a research note. The updated policy does not include a review of the Genesight dossier/Guided study, says the analyst. He views the change at United Healthcare as "minor" and keeps an Overweight rating on Myriad Genetics. Quirk continues to look for positive Genesight coverage.
03/21/19
RAJA
03/21/19
UPGRADE
Target $8
RAJA
Outperform
Raymond James upgrades Diplomat Pharmacy, sees number of potential suitors
Raymond James analyst John Ransom upgraded Diplomat Pharmacy (DPLO) to Outperform from Market Perform with an $8 price target. The stock closed yesterday up 14c to $5.86. Following the 56% share decline since the February earnings delay, Diplomat would represent value to a strategic buyer, Ransom tells investor in a research note. The analyst sees a number of potential buyers that would "covet" Diplomat Pharmacy's infusion franchise and could fold its large mail order business into an existing platform, including UnitedHealth (UNH), Cigna (CI), CVS Health (CVS), Anthem (ANTM) and Centene (CNC). Ransom thinks Diplomat's current fundamentals should motivate its board to step up its assessment of strategic options. He believes the company's collection of assets are underappreciated at current valuation levels.
04/10/19
CANT
04/10/19
NO CHANGE
CANT
Senate hearing a net positive for PBMs, says Cantor Fitzgerald
Cantor Fitzgerald analyst Steven Halper views yesterday's Senate hearing as a net positive for the pharmacy benefit managers. The PBMs represented were Cigna (CI), CVS Health (CVS), UnitedHealth (UNH), Humana (HUM) and Prime Therapeutics. Although the Senators were not supportive of the PBMs, the executives responded well to questions and put forth a solid effort to address concerns regarding their business model and incentives, Halper tells investors in a research note. Overall, he views the hearing as a net positive for PBMs "as the group was able to counter the negative sentiment with constructive responses, recognizing this story is far from over."
04/02/19
JEFF
04/02/19
UPGRADE
Target $107
JEFF
Buy
Quest, LabCorp upgraded to Buy ahead of UnitedHealth lab network rollout
Jefferies analyst Brian Tanquilut upgraded both Quest Diagnostics (DGX) and Laboratory Corp. of America (LH) to Buy from Hold on the belief that UnitedHealth's (UNH) rollout on July 1 of its preferred lab network will be a positive catalyst for both stocks. Quest and LabCorp's likely inclusion should bolster their organic growth beginning in 2020, Tanquilut tells investors in a research note. The analyst finds both stocks "compelling" with their 2019 outlooks "seemingly de-risked with fairly conservative guidance ranges" and 2020 consensus estimates "looking conservative." Further, Quest's and LabCorp's valuations are at below-historical relative averages, Tanquilut contends. The analyst raised his price target for Laboratory Corp. to $190 from $154 and for Quest to $107 from $93.
OXY Occidental Petroleum
$63.34

(0.00%)

03/26/19
OPCO
03/26/19
INITIATION
OPCO
Perform
Occidental Petroleum initiated with a Perform at Oppenheimer
Oppenheimer analyst Tim Rezvan started Occidental Petroleum with a Perform rating, stating that he is constructive on the company's strong Delaware Basin well results and improving efficiency metrics, but he sees near-term headwinds for earnings growth after peak 2018 earnings from the Chemicals and Midstream segments.
03/27/19
03/27/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Qualcomm (QCOM) initiated with a Neutral at JPMorgan. 2. Occidental Petroleum (OXY) initiated with a Perform at Oppenheimer. 3. Boeing (BA) resumed with a Buy at Citi. 4. Square (SQ) initiated with an Outperform at Macquarie. 5. Frontdoor (FTDR) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
02/19/19
SBSH
02/19/19
DOWNGRADE
Target $72
SBSH
Neutral
Occidental Petroleum downgraded to Neutral on lower midstream view at Citi
As previously reported, Citi analyst Robert Morris downgraded Occidental Petroleum to Neutral from Buy, citing the slowdown in drilling/completion activity in the Permian Basin and the anticipation of expanded Permian pipeline takeaway capacity in the coming quarters. The company's Q1 midstream net income guidance came in much lower than expected and he has lowered his midstream net income view to $495M from $1.1B. Given the lower midstream outlook, Morris cut his price target on Occidental Petroleum shares to $72 from $80.
02/19/19
SBSH
02/19/19
DOWNGRADE
SBSH
Neutral
Occidental Petroleum downgraded to Neutral from Buy at Citi
MDR McDermott
$9.15

(0.00%)

10/31/18
KEYB
10/31/18
DOWNGRADE
KEYB
Sector Weight
McDermott downgraded to Sector Weight from Overweight at KeyBanc
04/23/18
SBSH
04/23/18
NO CHANGE
SBSH
McDermott bid would need to be closer to $10/share to break CB&I deal, says Citi
Citi said Subsea 7's hostile bid for McDermott (MDR) for $7 per share was an interesting and unexpected move, but the firm believes any proposal would have to be closer to $10 per share to disrupt the current terms of the deal with CB&I (CBI), which it notes is well down the road toward closing. Citi's "strong sense" is that McDermott, with the support of a majority of its board, is intent on staying the course in closing the deal with CB&I, adding that it thinks McDermott is buying CB&I at or near the bottom of a backlog cycle.
GLD SPDR Gold Shares
$121.61

(0.00%)

WDC Western Digital
$51.86

(0.00%)

04/16/19
DBAB
04/16/19
UPGRADE
Target $60
DBAB
Buy
Deutsche sees favorable setup for Western Digital, upgrades shares to Buy
Deutsche Bank analyst Sidney Ho last night upgraded Western Digital to Buy from Hold and raised his price target for the shares to $60 from $45. The analyst is starting to see favorable data points in both hard disk drive and NAND that will support a "solid" second half of the year recovery for Western Digital's earnings. While the company's near-term earnings have downside risk due to weaker than expected NAND pricing, supply cuts across the NAND industry, along with a reacceleration of HDD demand, will likely lead to a stronger recovery off a lower base in the first half of 2019, Ho told investors in a research note. He expects management to highlight improved visibility on the upcoming earnings call, which he believes will be a positive catalyst for the shares. As such, Ho sees a favorable for Western Digital into the earnings print.
04/15/19
DBAB
04/15/19
UPGRADE
DBAB
Buy
Western Digital upgraded to Buy from Hold at Deutsche Bank
04/15/19
04/15/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Disney (DIS) upgraded to Neutral from Sell at BTIG with analyst Richard Greenfield saying the rating change was prompted more by the commentary from CEO Bob Iger on CNBC than by the company's investor day presentation unveiling Disney+. 2. Western Digital (WDC) upgraded to Buy from Neutral at Longbow with analyst Nikolay Todorov saying NAND fundamentals are bottoming and "there is a line of sight to cyclical recovery." 3. Dow Inc. (DOW), Huntsman (HUN), LyondellBasell (LYB), and Eastman Chemical (EMN) upgraded to Buy from Neutral at Nomura Instinet, while Olin (OLN) and Westlake Chemical (WLK) were upgraded to Neutral from Reduce. 4. Waste Management (WM) upgraded to Buy from Hold at Stifel with analyst Michael Hoffman saying even with potential divestitures to get the deal approved, adding Advanced Disposal "dramatically lowers" Waste Management's cost of capital, reduces capital spending, converts more of the fleet to CNG, and stimulates tuck-in activity that should all drive sustainable free cash flow growth. 5. Sony (SNE) upgraded to Buy from Hold at Jefferies. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/15/19
LBOW
04/15/19
UPGRADE
Target $65
LBOW
Buy
Longbow upgrades Western Digital with NAND recovery in 'line of sight'
Longbow Research analyst Nikolay Todorov upgraded Western Digital to Buy from Neutral with a $65 price target. The stock closed Friday up $1.00 to $51.83. NAND fundamentals are bottoming and "there is a line of sight to cyclical recovery," Todorov tells investors in a research note. The analyst believes NAND production is likely to be further rationalized with industry profitability under pressure and points out that pricing has recently shown signs of stabilization. Further, a hard drive revenue and gross margin recovery in the second half of 2019 does not appear to be fully contemplated by the Street, says Todorov. He sees an "asymmetric risk/reward" for Western Digital shares at current levels.
IBM IBM
$143.98

(0.00%)

03/26/19
BERN
03/26/19
NO CHANGE
BERN
Red Hat worth $190/share 'even as stand alone entity,' says Bernstein
Bernstein analyst Zane Chrane notes that Red Hat's (RHT) Q4 results are unlikely to have a material impact on the stock price given the expected acquisition by IBM (IBM) in the second half of 2019. However, strong growth in emerging products, continued reacceleration in RHEL revenue, and robust growth in deferred revenue and backlog all suggest the company is having increasing success in cross-selling its hybrid cloud solutions to large enterprise customers, he contends, adding that this quarter's results were "strong across the board," suggesting that the pending IBM deal is not having any negative impact on the company's execution. Chrane believes Red Hat is worth $190 per share "even as a stand-alone entity."
03/15/19
BMOC
03/15/19
DOWNGRADE
Target $53
BMOC
Market Perform
Oracle downgraded to Market Perform from Outperform at BMO Capital
BMO Capital analyst Keith Bachman downgraded Oracle (ORCL) to Market Perform from Outperform with an unchanged price target of $53 following last night's fiscal Q3 results. The stock in premarket trading is down 3%, or $1.65, to $51.40. The analyst believes Oracle can sustain ~2% constant currency revenue growth, but is "dubious" the company can improve its revenue growth rates. He does not think autonomous database or gradual unfolding of the cloud enterprise resource planning market will help Oracle's growth in fiscal 2020. As demonstrated by IBM (IBM) over the years, an aggressive buyback will not be enough to push the shares meaningfully higher without improved top-line results, Bachman tells investors in a post-earnings research note. As such, he sees a balanced risk/reward profile at current share levels.
04/11/19
FBCO
04/11/19
INITIATION
Target $173
FBCO
Outperform
IBM initiated with an Outperform at Credit Suisse
Credit Suisse analyst Matt Cabral initiated IBM (IBM) with an Outperform rating and a price target of $173. The analyst cites the impact of the company's pending Red Hat (RHT) acquisition generating synergies while bringing together the industry expertise and incumbency to "help customers move to hybrid". Cabral adds that while IBM has sustainable free cash flow of about $12B ex-Red Hat, he expects the deal to be cash flow accretive in the first year, becoming the company's "main driver of growth".
02/11/19
PIPR
02/11/19
NO CHANGE
PIPR
Piper storage survey positive for Pure Storage, Nutanix, NetApp
Piper Jaffray conducted its fiscal Q4 Storage Reseller Survey by collecting feedback from 28 resellers and distributors. While only five of 14 vendors had net positive results versus six of the 14 last quarter, the firm saw "strong results" for Pure Storage (PSTG), Rubrik, Nutanix (NTNX), Veeam and NetApp (NTAP), analyst Andrew Nowinski told investors earlier in a research note. Pure Storage also had the strongest pipeline heading into the April quarter, added the analyst. The company's results sharply improved in the survey, with 67% of resellers citing "Above Plan" results, the highest level seen in three years, says Nowinski. The stock in early trading is up 19c to $18.47. Of those surveyed by Piper, 36% of resellers said they saw a negative impact from the U.S. government shutdown, with Dell (DELL), HP/3PAR (HPQ) and IBM (IMB) the most impacted.
SBUX Starbucks
$76.15

(0.00%)

04/08/19
04/08/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. General Electric (GE) downgraded to Underweight from Neutral at JPMorgan with analyst Stephen Tusa saying with the stock up 38% year-to-date, many investors are underestimating the severity of the challenges and underlying risks at GE, while overestimating the value of "small positives." 2. Starbucks (SBUX) downgraded to Neutral from Buy at UBS with analyst Dennis Geiger saying the risk/reward on shares "appears balanced" with the stock up 55% since June. 3. Boeing (BA) downgraded to Neutral from Buy at BofA/Merrill with analyst Ronald Epstein citing the company's announcement that it will cut 737 production rates to 42 per month from 52 per month, which he takes to likely mean that the 737 delay could last longer than previously expected. 4. Micron (MU) downgraded to Market Perform from Outperform at Cowen with analyst Karl Ackerman saying his field work indicates Micron's profitability will decline again in calendar year 2020. 5. Roku (ROKU) downgraded to Sell from Neutral at Citi with analyst Mark May saying the stock is up 110% year-to-date and near all-time highs. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
04/05/19
STFL
04/05/19
NO CHANGE
Target $700
STFL
Hold
Chipotle price target raised to $700 after restaurant sentiment survey at Stifel
Stifel analyst Chris O'Cull said his recent survey of investors indicated that 33% think restaurant fundamentals deteriorated during Q1 relative to their initial expectations at the beginning of the quarter. McDonald's (MCD) was the only large-cap restaurant stock voted to outperform heading into earnings season while Chipotle (CMG) and Domino's (DPZ) were investors' top small-to-mid-cap picks for earnings outperformance, noted O'Cull. Among large-cap stocks, the largest number of investors surveyed pointed to Starbucks (SBUX) as most likely to underperform in the near-term, the analyst added. O'Cull raised his 2019 and 2020 EPS estimates for Chipotle based on his view that Q4 momentum has likely built in early 2019 and increased his price target on the shares to $700 from $500, but he maintains a Hold rating on Chipotle shares.
04/08/19
UBSW
04/08/19
DOWNGRADE
Target $78
UBSW
Neutral
Starbucks downgraded to Neutral from Buy at UBS
UBS analyst Dennis Geiger downgraded Starbucks to Neutral from Buy while raising his price target for the shares to $78 from $72. The stock closed Friday up 68c to $75.03. The risk/reward on shares "appears balanced" with the stock up 55% since June, Geiger tells investors in a research note. He believes Starbucks is better positioned going forward with improved same-store-sales momentum and streamlined operations. However, the shares "reflect this and expectations are now elevated," says Geiger. The analyst adds that while repurchase activity and upside to forecasts "could support further multiple expansion," he sees risks from "downside to more elevated sales/earnings expectations as an offset.
04/10/19
PIPR
04/10/19
NO CHANGE
Target $70
PIPR
Neutral
Starbucks price target raised to $70 from $60 at Piper Jaffray
Piper Jaffray analyst Nicole Miller Regan raised her price target for Starbucks to $70 from $60 and keeps a Neutral rating on the name following March channel checks. In March, our Starbucks checks were steady in the positive mid-single-digit range, Regan tells investors in a research note. She notes, however, that her Starbucks checks, on average, have been approximately 120 basis points below actual results over the last four quarters. As such, the analyst is maintaining her positive 3% fiscal Q2 same-store sales estimate for the Americas segment. Regan remains Neutral rated on Starbucks with an "incrementally positive bias." It appears the potential overhang related to sales momentum and/or operational execution in the Americas segment has been partially removed, says the analyst.
GS Goldman Sachs
$199.77

(0.00%)

03/01/19
SBSH
03/01/19
NO CHANGE
SBSH
Neutral
Goldman Sachs faces 'tough legal setup' in 1MDB case, says Citi
Goldman Sachs' alleged role in the ongoing 1MDB scandal has weighed on the stock since November, Citi analyst Keith Horowitz tells investors in a research note. After researching the case and speaking with a subject matter expert, the analyst thinks Goldman "faces a tough legal setup" in the 1MDB case. He expects the company to settle with regulators and estimates a range of penalties from $1.5B to $9.0B, with a base case of $4B-$5B. He sees suspended business activities as unlikely. Despite the 14% underperformance since November, Goldman shares are fairly valued given continued 1MDB overhang, Horowitz tells investors in a research note. He keeps a Neutral rating on the shares.
03/25/19
JEFF
03/25/19
NO CHANGE
JEFF
Jefferies downgrades Financials to Underweight on 'shocking' Fed meeting
Jefferies analyst Steven DeSanctis is "very surprised" by last week's Federal Reserve's decision taking rate hikes completely off table in 2019. The "shocking" Fed meeting means lower rates for longer, which is not good for Financials, DeSanctis tells investors in a research note. A "lack of catalysts and weaker earnings growth" going forward for the entire sector, not just banks, means an Underweight rating on the space makes sense, says the analyst. As such, he downgraded his rating on the Financial sector to Underweight from Market Weight. Publicly traded companies in the space include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
03/26/19
WEDB
03/26/19
NO CHANGE
WEDB
Apple Card 'a slight negative' for Visa, says Wedbush
Wedbush analyst Moshe Katri believes Apple's announcement of a physical Apple card is a "slight negative" for Outperform rated Visa (V) and a "slight positive" for Outperform rated MasterCard (MA), assuming it gains traction. The physical Apple card is a partnership with Goldman Sachs (GS) and Mastercard.
04/16/19
BMOC
04/16/19
NO CHANGE
Target $260
BMOC
Market Perform
Goldman Sachs price target lowered to $260 from $262 at BMO Capital
BMO Capital analyst James Fotheringham lowered his price target on Goldman Sachs (GS) to $260 and kept his Market Perform rating after its Q1 results. The analyst says that in spite of the company's "broad-based beat", he is lowering his FY20 EPS view to $27.06 from $27.66 due to lower expected Investing and Lending net revenues along with higher credit provisions. Fotheringham prefers Morgan Stanley (MS) to Goldman Sachs since the two trade at a similar two-year-forward rolling earnings multiple, but the wealth management-oriented earnings mix of the former implies a premium that he expects to materialize.

TODAY'S FREE FLY STORIES

PFE

Pfizer

$39.37

-0.5 (-1.25%)

, LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

17:07
04/18/19
04/18
17:07
04/18/19
17:07
Hot Stocks
Pfizer, Lilly say tanezumab met 2/3 co-primary endpoints in Phase 3 study »

Pfizer Inc. (PFE) and Eli…

PFE

Pfizer

$39.37

-0.5 (-1.25%)

LLY

Eli Lilly

$115.20

-1.23 (-1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

  • 30

    Apr

  • 30

    Apr

  • 06

    May

  • 07

    May

  • 08

    May

  • 09

    May

  • 18

    May

FAST

Fastenal

$71.08

0.95 (1.35%)

17:06
04/18/19
04/18
17:06
04/18/19
17:06
Hot Stocks
Fastenal approves two-for-one stock split »

Fastenal Company…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 05

    Jun

AKRX

Akorn

$2.77

-0.16 (-5.46%)

, IQV

Iqvia

$133.02

0.76 (0.57%)

17:02
04/18/19
04/18
17:02
04/18/19
17:02
Hot Stocks
Akorn gets FDA approval for Loteprednol Etabonate Ophthalmic »

Akorn (AKRX) announced…

AKRX

Akorn

$2.77

-0.16 (-5.46%)

IQV

Iqvia

$133.02

0.76 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 07

    May

  • 05

    Jun

  • 23

    Jun

ATR

AptarGroup

$108.21

0.41 (0.38%)

17:01
04/18/19
04/18
17:01
04/18/19
17:01
Hot Stocks
AptarGroup raises dividend 6%, announces new $350M share repurchase plan »

The Board of Directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    May

  • 01

    May

  • 01

    May

  • 07

    May

BBY

Best Buy

$73.65

0.24 (0.33%)

17:00
04/18/19
04/18
17:00
04/18/19
17:00
Hot Stocks
Best Buy CEO Joly sells 171,711 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    May

ISRG

Intuitive Surgical

$528.04

3.29 (0.63%)

16:59
04/18/19
04/18
16:59
04/18/19
16:59
Hot Stocks
Intuitive Surgical tightens FY19 procedure growth view to 15%-17% from 13%-17% »

Sees FY19 operating…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 25

    Apr

  • 03

    May

BHB

Bar Harbor Bankshares

$25.71

-0.42 (-1.61%)

16:58
04/18/19
04/18
16:58
04/18/19
16:58
Hot Stocks
Bar Harbor Bankshares raises quarterly dividend 10% to 22c per share »

Bar Harbor Bankshares…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

, EA

Electronic Arts

$93.13

1.19 (1.29%)

16:55
04/18/19
04/18
16:55
04/18/19
16:55
Conference/Events
Wedbush digital media analyst to hold an analyst/industry conference call »

Digital Media Analyst…

ATVI

Activision Blizzard

$45.29

0.31 (0.69%)

EA

Electronic Arts

$93.13

1.19 (1.29%)

GME

GameStop

$8.78

-0.15 (-1.68%)

NTDOY

Nintendo

$0.00

(0.00%)

TTWO

Take-Two

$90.73

0.97 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 02

    May

  • 07

    May

  • 13

    May

  • 29

    May

  • 13

    Nov

SCOR

comScore

$12.91

-0.38 (-2.86%)

16:46
04/18/19
04/18
16:46
04/18/19
16:46
Hot Stocks
comScore names Kathy Bachmann as COO, effective April 17 »

On April 12, the Board of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

SRE

Sempra Energy

$127.42

0.1 (0.08%)

16:46
04/18/19
04/18
16:46
04/18/19
16:46
Hot Stocks
Sempra Energy receives FERC authorization for Texas project »

Sempra Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    May

  • 21

    May

SPR

Spirit AeroSystems

$85.57

-0.12 (-0.14%)

, BA

Boeing

$380.02

2.48 (0.66%)

16:45
04/18/19
04/18
16:45
04/18/19
16:45
Hot Stocks
Boeing, Spirit Aero reach pact to cover production costs for B737 program »

According to a regulatory…

SPR

Spirit AeroSystems

$85.57

-0.12 (-0.14%)

BA

Boeing

$380.02

2.48 (0.66%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 29

    May

  • 05

    Jun

16:45
04/18/19
04/18
16:45
04/18/19
16:45
General news
Treasury Market Summary: »

Treasury Market Summary:…

16:40
04/18/19
04/18
16:40
04/18/19
16:40
General news
Fed Balance Sheet Level data reported »

Week of 4/17 Fed Balance…

16:40
04/18/19
04/18
16:40
04/18/19
16:40
General news
Money Supply M2 Weekly Change data reported »

Week of 4/8 Money Supply…

BLK

BlackRock

$465.67

-1.99 (-0.43%)

16:38
04/18/19
04/18
16:38
04/18/19
16:38
Hot Stocks
BlackRock CFO sells 2,750 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Jun

  • 27

    Oct

TRV

Travelers

$138.82

2.93 (2.16%)

, HON

Honeywell

$169.01

6.09 (3.74%)

16:38
04/18/19
04/18
16:38
04/18/19
16:38
On The Fly
Fly Intel: Wall Street's top stories for Thursday »

The S&P 500 notched a…

TRV

Travelers

$138.82

2.93 (2.16%)

HON

Honeywell

$169.01

6.09 (3.74%)

AXP

American Express

$113.67

1.89 (1.69%)

PM

Philip Morris

$84.53

-0.96 (-1.12%)

ZM

Zoom Video

$62.00

(0.00%)

PINS

Pinterest

$24.46

(0.00%)

CGC

Canopy Growth

$44.43

1.6 (3.74%)

ACRGF

Acreage Holdings

$0.00

(0.00%)

FB

Facebook

$178.28

-0.49 (-0.27%)

BX

Blackstone

$38.65

2.74 (7.63%)

ADTN

Adtran

$16.60

2.055 (14.13%)

URI

United Rentals

$136.05

10.25 (8.15%)

CHKP

Check Point

$120.01

-9.56 (-7.38%)

SNBR

Sleep Number

$39.23

-8.76 (-18.25%)

SKX

Skechers

$31.60

-3.68 (-10.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 18

    Apr

  • 24

    Apr

  • 24

    Apr

  • 29

    Apr

  • 01

    May

  • 06

    May

  • 07

    May

  • 07

    May

  • 07

    May

  • 08

    May

  • 14

    May

  • 14

    May

  • 15

    May

  • 17

    May

  • 18

    May

  • 03

    Jun

  • 05

    Jun

  • 11

    Jun

  • 13

    Nov

  • 18

    Apr

  • 18

    Apr

GBCI

Glacier Bancorp

$41.70

-0.7 (-1.65%)

16:36
04/18/19
04/18
16:36
04/18/19
16:36
Earnings
Glacier Bancorp reports Q1 EPS 58c, consensus 58c »

Reports Q1 book value per…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Apr

  • 24

    Apr

BLMN

Bloomin' Brands

$19.24

0.42 (2.23%)

16:34
04/18/19
04/18
16:34
04/18/19
16:34
Recommendations
Bloomin' Brands analyst commentary at Tigress Financial »

Bloomin' Brands…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Apr

  • 30

    Apr

APHA

Aphria

$7.65

-0.165 (-2.11%)

16:32
04/18/19
04/18
16:32
04/18/19
16:32
Hot Stocks
Aphria subsidiary secures cannabis cultivation license in Germany »

Aphria Inc. announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNP

CenterPoint Energy

$30.29

0.28 (0.93%)

, SO

Southern Company

$51.95

-0.22 (-0.42%)

16:32
04/18/19
04/18
16:32
04/18/19
16:32
Hot Stocks
CenterPoint Energy names Xia Liu as CFO, effective April 22 »

CenterPoint Energy (CNP)…

CNP

CenterPoint Energy

$30.29

0.28 (0.93%)

SO

Southern Company

$51.95

-0.22 (-0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 01

    May

  • 09

    May

  • 21

    May

  • 21

    May

BANF

BancFirst

$55.58

-0.34 (-0.61%)

16:30
04/18/19
04/18
16:30
04/18/19
16:30
Earnings
BancFirst reports Q1 EPS 96c, consensus 92c »

At March 31, 2019, the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:30
04/18/19
04/18
16:30
04/18/19
16:30
Options
Preliminary option volume of 20.4M today »

Preliminary option volume…

ZSAN

Zosano Pharma

$3.41

-0.11 (-3.13%)

16:28
04/18/19
04/18
16:28
04/18/19
16:28
Hot Stocks
Zosano Pharma CEO buys 100K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SJI

South Jersey Industries

$31.46

-0.16 (-0.51%)

16:26
04/18/19
04/18
16:26
04/18/19
16:26
Hot Stocks
Elizabethtown Gas files rate case with NJBPU »

Elizabethtown Gas, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    May

  • 21

    May

BCBP

BCB Bancorp

$13.09

0.08 (0.61%)

16:21
04/18/19
04/18
16:21
04/18/19
16:21
Earnings
BCB Bancorp reports Q1 EPS 32c, consensus 30c »

Total cash and cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

  • 08

    May

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.